Pharmaceuticals news FT.com

Novo hunts for ‘maximum potential’ from obesity drug CagriSema

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target

Jun 22, 2025 - 15:05
 0
Novo hunts for ‘maximum potential’ from obesity drug CagriSema
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target
Read More

Tags:

Previous Article

How Fast Can The Suzuki Hayabusa Really Go? Here's What Riders Have Clocked

Next Article

Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

Related Posts

Novo Nordisk partners with US biotech to boost pipeline of new obesity drugs

Novo Nordisk partners with US biotech to boost pipeline...

May 14, 2025  0

How Trump’s tariffs threaten Ireland’s pharma fortune

How Trump’s tariffs threaten Ireland’s pharma fortune

May 21, 2025  0

GSK buys Boston Pharmaceuticals’ new liver disease drug for up to $2bn

GSK buys Boston Pharmaceuticals’ new liver disease drug...

May 14, 2025  0